MRG002
Phase 2Small molecule
MRG002 is one of 81 small molecule programs targeting Biliary Tract Cancer. It is currently in Phase 2.
3
Indications
10
Total Trials
2
Active Trials
80
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Halaven
EisaiPreclinical
Nolvadex
SSan Diego Pacific Oncology & Hematology Associates
Preclinical
Megace
Bristol-Myers SquibbPreclinical
MRG002
SShanghai Miracogen Inc.
Phase 2
Lupron
EEastern Cooperative Oncology Group
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Chantix
PPrism Pharmaceuticals
Preclinical
QS21
MMemorial Sloan Kettering Cancer Center
Preclinical
Apatinib Mesylate
BBukwang Pharmaceutical
Preclinical
Beta Blocker
WWeill Medical College of Cornell University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Breast Cancer3 trials
Biliary Tract Cancer1 trial
HER2-positive Advanced Solid Tumors1 trial
Locally Advanced1 trial
3 more indications
Gastric/Gastroesophageal Junction Cancer1 trial
Metastatic Urothelial Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MRG002. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- SShanghai Miracogen Inc.